Lehman & Derafelo Financial Resources LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 0.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 203,448 shares of the biopharmaceutical company’s stock after purchasing an additional 845 shares during the quarter. Pfizer comprises about 2.3% of Lehman & Derafelo Financial Resources LLC’s holdings, making the stock its 9th largest holding. Lehman & Derafelo Financial Resources LLC’s holdings in Pfizer were worth $6,653,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of PFE. Sunbelt Securities Inc. increased its stake in Pfizer by 1.8% during the fourth quarter. Sunbelt Securities Inc. now owns 186,794 shares of the biopharmaceutical company’s stock worth $7,319,000 after acquiring an additional 3,235 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services increased its stake in Pfizer by 5.1% during the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 124,915 shares of the biopharmaceutical company’s stock worth $4,077,000 after acquiring an additional 6,012 shares during the last quarter. IMS Capital Management increased its stake in Pfizer by 249.3% during the first quarter. IMS Capital Management now owns 24,791 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 17,694 shares during the last quarter. Woodstock Corp increased its stake in Pfizer by 0.6% during the first quarter. Woodstock Corp now owns 136,295 shares of the biopharmaceutical company’s stock worth $4,449,000 after acquiring an additional 800 shares during the last quarter. Finally, Fulton Bank N.A. increased its stake in Pfizer by 1.4% during the first quarter. Fulton Bank N.A. now owns 168,029 shares of the biopharmaceutical company’s stock worth $5,484,000 after acquiring an additional 2,273 shares during the last quarter. 70.20% of the stock is owned by hedge funds and other institutional investors.

PFE has been the subject of several recent analyst reports. UBS Group raised their target price on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday. TheStreet upgraded Pfizer from a “c+” rating to a “b” rating in a research report on Monday, June 1st. Morgan Stanley raised their price target on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Barclays lowered their price target on Pfizer from $37.00 to $35.00 in a research report on Monday, June 1st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $38.95.

NYSE:PFE traded down $0.26 during midday trading on Friday, reaching $38.48. The company had a trading volume of 27,042,691 shares, compared to its average volume of 32,108,124. The firm has a market capitalization of $213.75 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 3.12 and a beta of 0.68. The stock’s fifty day simple moving average is $34.75 and its 200-day simple moving average is $35.79. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $40.97. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The firm had revenue of $11.80 billion during the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a return on equity of 25.10% and a net margin of 28.80%. Pfizer’s revenue was down 11.0% compared to the same quarter last year. During the same period last year, the business posted $0.80 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be issued a $0.38 dividend. The ex-dividend date is Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a yield of 3.95%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total transaction of $78,799.53. Following the completion of the sale, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.08% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is the Russell 2000 Index?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.